Drug Profile
MK 944A
Latest Information Update: 24 Mar 2010
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antivirals
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections